NeuroMetrix

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. It focuses on the sale of medical equipment and consumables. Its products include DPNCheck, Quell, and ADVANCE system. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroMetrix reports Q2 revenue decline but shows promise in Quell line

NeuroMetrix faced revenue decline due to DPNCheck product line, offset by strong growth in the Quell product line.
Efficient cost management reflected in a solid gross margin rate of 64% and reduced operating expenses.
The company maintains a healthy financial position with significant working capital and liquid assets.
Strategic review aims to enhance shareholder value and explore new growth avenues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2022 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022.

NeuroMetrix Appoints Brad Fluegel to its Board of Directors

Bright Green Corp

China Liberal Education Holdings 

DecisionPoint Systems

Visionary Education Technology Holdings Group Inc

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring order to the markets.

6 Stocks Halted In Thursday's Session: Here's Why

Indaptus Therapeutics

Mullen Automotive

Here are three penny stocks for your watchlist right now The post Hot Penny Stocks to Watch Right Now? 3 For Your List in May appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch Right Now? 3 For Your List in May

Today, investors in NeuroMetrix and NURO stock are cheering an announcement that the FDA has approved the company to market its Quell device. The post Why Is NeuroMetrix (NURO) Stock Up 70% Today?

Why Is NeuroMetrix (NURO) Stock Up 70% Today?

NeuroMetrix Inc (NASDAQ: NURO) shares are trading higher by 30.10% at $4.06 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia. Quell Fibromyalgia is a transcutaneous electrical nerve.

Why NeuroMetrix Shares Are Skyrocketing

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021.

NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

NeuroMetrix, Inc. (NASDAQ:NURO ) Q1 2022 Earnings Conference Call April 26, 2022 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - President and Chief Executive Officer Operator Good morning and welcome to the NeuroMetrix First Quarter 2022 Earnings Conference Call. My name is Olivia and I will be your moderator on the call.

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2022 Results - Earnings Call Transcript

WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

NeuroMetrix Reports Q1 2022 Financial Results

WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on April 26, 2022 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

NeuroMetrix Inc's (NASDAQ: NURO) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID").  Quell is an advanced, non-invasive neuromodulation technology.

NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome

WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). The trial will be conducted at the Baylor College of Medicine in collaboration with the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP). The principal investigator is Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine.

NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome

NeuroMetrix, Inc.'s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call Transcript

WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

NeuroMetrix Reports Q4 and Full Year 2021 Financial Results

WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on January 27, 2022 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call

NeuroMetrix Inc. (NASDAQ: NURO) shot up 35% after announcing that the FDA awarded it Breakthrough Device Designation for its Quell technology. This innovative technology is designed to help reduce severe to moderate chemo symptoms that persist for at least six months after one is done with chemo.

Neurometrix up 35% after receiving FDA Breakthrough Designation for its Quell tech

NeuroMetrix (NURO) stock is rocketing higher on Tuesday thanks to the FDA granting it Breakthrough Designation for one of its devices. The post NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today appeared first on InvestorPlace.

NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today

The FDA has granted Breakthrough Designation to NeuroMetrix Inc's (NASDAQ:NURO) Quell technology for reducing moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have persisted for at least 6-months following the end of chemotherapy. There are no FDA-approved treatments for CIPN, and those that are used have limited effectiveness and have side effects.

NeuroMetrix Shares Rally On FDA Breakthrough Tag For Neurostimulation Device

WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for reducing moderate to severe symptoms of chemotherapy induced peripheral neuropathy that have persisted for at least 6-months following the end of chemotherapy.

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

BARK

Nxt-ID

Tellurian

Webull penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 On Webull With Bullish User Ratings

WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Brandi Damkier as Vice President, Clinical Partnerships. Ms. Damkier will be responsible for expanding the Company's DPNCheck® clinical partnerships and advancing the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies. It is often used to stage the severity of Diabetic Peripheral Neuropathy (DPN), which is the most common specific cause of peripheral nerve disease and a ubiquitous long-term complication of diabetes that may progress to foot ulcers and amputation.

NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships

WOBURN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022. Dr. Gozani's video presentation will be available on-demand for 90 days starting on Monday, January 10, 2022 at 7:00 A.M. (ET). It may be accessed here and also on the NeuroMetrix, Inc. Investor Relations page at www.NeuroMetrix.com . Dr. Gozani will highlight the Company's product portfolio, growth initiatives and outlook for 2022.

NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022

NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q3 2021 Results - Earnings Call Transcript

WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders.

NeuroMetrix Reports Q3 2021 Financial Results

WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell will be responsible for growing the Company's DPNCheck® business with a primary focus on the Medicare Advantage population, and more broadly, expanding the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies. It is often used to stage the severity of Diabetic Peripheral Neuropathy (DPN), which is the most common specific cause of peripheral nerve disease and a ubiquitous long-term complication of diabetes that may lead to foot ulcers and amputation.

News for NeuroMetrix Stock (NURO)